186 related articles for article (PubMed ID: 15611295)
1. Role of Dok-1 and Dok-2 in leukemia suppression.
Niki M; Di Cristofano A; Zhao M; Honda H; Hirai H; Van Aelst L; Cordon-Cardo C; Pandolfi PP
J Exp Med; 2004 Dec; 200(12):1689-95. PubMed ID: 15611295
[TBL] [Abstract][Full Text] [Related]
2. Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia.
Yasuda T; Shirakata M; Iwama A; Ishii A; Ebihara Y; Osawa M; Honda K; Shinohara H; Sudo K; Tsuji K; Nakauchi H; Iwakura Y; Hirai H; Oda H; Yamamoto T; Yamanashi Y
J Exp Med; 2004 Dec; 200(12):1681-7. PubMed ID: 15611294
[TBL] [Abstract][Full Text] [Related]
3. Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins.
Di Cristofano A; Carpino N; Dunant N; Friedland G; Kobayashi R; Strife A; Wisniewski D; Clarkson B; Pandolfi PP; Resh MD
J Biol Chem; 1998 Feb; 273(9):4827-30. PubMed ID: 9478921
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine phosphorylation of p62dok by p210bcr-abl inhibits RasGAP activity.
Kashige N; Carpino N; Kobayashi R
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2093-8. PubMed ID: 10688886
[TBL] [Abstract][Full Text] [Related]
5. p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl).
Di Cristofano A; Niki M; Zhao M; Karnell FG; Clarkson B; Pear WS; Van Aelst L; Pandolfi PP
J Exp Med; 2001 Aug; 194(3):275-84. PubMed ID: 11489947
[TBL] [Abstract][Full Text] [Related]
6. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias.
Honda H; Oda H; Suzuki T; Takahashi T; Witte ON; Ozawa K; Ishikawa T; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(6):2067-75. PubMed ID: 9490692
[TBL] [Abstract][Full Text] [Related]
7. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
8. p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells.
Carpino N; Wisniewski D; Strife A; Marshak D; Kobayashi R; Stillman B; Clarkson B
Cell; 1997 Jan; 88(2):197-204. PubMed ID: 9008160
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.
Eiring AM; Neviani P; Santhanam R; Oaks JJ; Chang JS; Notari M; Willis W; Gambacorti-Passerini C; Volinia S; Marcucci G; Caligiuri MA; Leone GW; Perrotti D
Blood; 2008 Jan; 111(2):816-28. PubMed ID: 17925491
[TBL] [Abstract][Full Text] [Related]
10. Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia.
Miyazaki K; Yamasaki N; Oda H; Kuwata T; Kanno Y; Miyazaki M; Komeno Y; Kitaura J; Honda Z; Warming S; Jenkins NA; Copeland NG; Kitamura T; Nakamura T; Honda H
Blood; 2009 May; 113(19):4702-10. PubMed ID: 19234145
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.
Warmuth M; Danhauser-Riedl S; Hallek M
Ann Hematol; 1999 Feb; 78(2):49-64. PubMed ID: 10089019
[TBL] [Abstract][Full Text] [Related]
12. The roles of Dok family adapters in immunoreceptor signaling.
Mashima R; Hishida Y; Tezuka T; Yamanashi Y
Immunol Rev; 2009 Nov; 232(1):273-85. PubMed ID: 19909370
[TBL] [Abstract][Full Text] [Related]
13. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
14. Detection of P210bcr-abl in mature granulocytes from Ph1-positive chronic myelogenous leukemia patients by an immunoblotting method.
Kuwao F; Takahashi I
Leukemia; 1993 Aug; 7(8):1168-73. PubMed ID: 8350617
[TBL] [Abstract][Full Text] [Related]
15. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
16. Functional interaction of RasGAP-binding proteins Dok-1 and Dok-2 with the Tec protein tyrosine kinase.
Gérard A; Favre C; Garçon F; Némorin JG; Duplay P; Pastor S; Collette Y; Olive D; Nunès JA
Oncogene; 2004 Feb; 23(8):1594-8. PubMed ID: 14647425
[TBL] [Abstract][Full Text] [Related]
17. Model mice for BCR/ABL-positive leukemias.
Honda H; Hirai H
Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
[TBL] [Abstract][Full Text] [Related]
18. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine phosphorylated proteins in chronic myelogenous leukemia.
Frackelton AR; Kumar PS; Kannan B; Clark JW
Leuk Lymphoma; 1993; 11 Suppl 1():125-9. PubMed ID: 7504542
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.
Perrotti D; Cesi V; Trotta R; Guerzoni C; Santilli G; Campbell K; Iervolino A; Condorelli F; Gambacorti-Passerini C; Caligiuri MA; Calabretta B
Nat Genet; 2002 Jan; 30(1):48-58. PubMed ID: 11753385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
